• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    iRadimed Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    5/29/25 4:15:13 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care
    Get the next $IRMD alert in real time by email
    0001325618false00013256182025-05-292025-05-29

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    ​

    FORM 8-K

    ​

    CURRENT REPORT PURSUANT

    TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): May 29, 2025

    IRADIMED CORPORATION

    (Exact name of registrant as specified in its charter)

    Delaware

    (State or other jurisdiction of incorporation)

    001-36534

    73-1408526

    (Commission File Number)

    (IRS Employer Identification No.)

     

     

    1025 Willa Springs Dr., Winter Springs, FL

    32708

           (Address of principal executive offices)

    (Zip Code)

    ​

    (407) 677-8022

    (Registrant’s telephone number, including area code)

    ​

    (Former name or former address, if changed since last report)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class:

     

    Trading Symbol

     

    Name of each exchange on which registered:

    Common stock, par value $0.0001

     

    IRMD

     

    NASDAQ Capital Market

    ​

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

    ​

    ​

    ​

    ​

    ​

    Item 8.01 Other Items    

    ​

    On May 29, 2025, iRadimed Corporation (the “Company”) issued a press release (the “Press Release”) announcing that the U.S. Food and Drug Administration has granted 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System (the “MRidium® 3870”).

    ​

    The MRidium® 3870 is an advanced,  Magnetic Resonance Imaging (“MRI”) compatible infusion pump that extends the Company’s unique position as the world’s only supplier of non-magnetic MRI infusion pump devices, addressing growing demands for safe and reliable fluid delivery in diagnostic imaging. The MRidium® 3870 features a non-magnetic ultrasonic pump motor, non-interfering radio frequency emissions, and non-ferrous components, ensuring seamless performance in high-magnetic-field environments.

    ​

    A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

    ​

    Item 9.01     Financial Statements and Exhibits.

    ​

    (d)     Exhibits

    ​

    Exhibit No.

    Description

    99.1

    Press release, dated May 29, 2025.

    104

    Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

    ​

    ​

    ​

    ​

    ​

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

     

    IRADIMED CORPORATION

     

     

     

     

    Date: May 29, 2025

    By:

    /s/ John Glenn                                    

     

    Name:

    John Glenn

     

    Title:

    Chief Financial Officer

     

     

    ​

    ​

    ​

    ​

    Get the next $IRMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRMD

    DatePrice TargetRatingAnalyst
    4/12/2023$50.00Buy
    Lake Street
    More analyst ratings

    $IRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Allen Monty K sold $76,148 worth of shares (1,102 units at $69.10), decreasing direct ownership by 5% to 19,898 units (SEC Form 4)

    4 - IRADIMED CORP (0001325618) (Issuer)

    8/6/25 8:00:05 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    CHIEF FINANCIAL OFFICER Glenn John converted options into 5,796 shares and covered exercise/tax liability with 1,412 shares, increasing direct ownership by 50% to 13,151 units (SEC Form 4)

    4 - IRADIMED CORP (0001325618) (Issuer)

    6/23/25 8:00:21 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form 4 filed by CHIEF FINANCIAL OFFICER Glenn John

    4/A - IRADIMED CORP (0001325618) (Issuer)

    4/7/25 4:10:04 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    $IRMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IRADIMED CORPORATION Reports Record Second Quarter 2025 Financial Results

    Announces Regular Quarterly Cash Dividend of $0.17 Per Share Raises Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $20.4 million for the second quarter of 2025, an increase of $2.5 million, or 14%, compared to the same period in 2024.Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the second quarter of 2025, which are increases of 18% and 17%, respectively, compared to the same period in 2024.Declares a regular quarterly cash dividend of $0.17 per share of common stock for the third quarter of 2025, payable on August 28, 2025. ORLANDO, Fla., Aug. 01, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company" or "Iradimed") (NASDAQ

    8/1/25 8:30:00 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025

    ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 second quarter financial results before the market opens on Friday, August 1, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI52cf21ec526142b8b6142d07c87cfcf9. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available re

    7/25/25 4:05:00 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    IRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump System

    WINTER SPRINGS, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Iradimed Corporation (NASDAQ:IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System. This advanced, MRI-compatible infusion pump extends Iradimed's unique position as the world's only supplier of non-magnetic MRI infusion pump devices, established with our first-generation device in 2005. The MRidium® 3870 is poised to strengthen Iradimed's leadership for MRI-compatible infusion, addressing growing demands for safe and reliable fluid delivery in diagnostic imagi

    5/29/25 8:30:00 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    $IRMD
    SEC Filings

    View All

    SEC Form 144 filed by iRadimed Corporation

    144 - IRADIMED CORP (0001325618) (Subject)

    8/6/25 12:20:05 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by iRadimed Corporation

    10-Q - IRADIMED CORP (0001325618) (Filer)

    8/1/25 4:06:06 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    iRadimed Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - IRADIMED CORP (0001325618) (Filer)

    8/1/25 8:32:35 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    $IRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on iRadimed with a new price target

    Lake Street initiated coverage of iRadimed with a rating of Buy and set a new price target of $50.00

    4/12/23 9:17:10 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    $IRMD
    Financials

    Live finance-specific insights

    View All

    IRADIMED CORPORATION Reports Record Second Quarter 2025 Financial Results

    Announces Regular Quarterly Cash Dividend of $0.17 Per Share Raises Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $20.4 million for the second quarter of 2025, an increase of $2.5 million, or 14%, compared to the same period in 2024.Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the second quarter of 2025, which are increases of 18% and 17%, respectively, compared to the same period in 2024.Declares a regular quarterly cash dividend of $0.17 per share of common stock for the third quarter of 2025, payable on August 28, 2025. ORLANDO, Fla., Aug. 01, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company" or "Iradimed") (NASDAQ

    8/1/25 8:30:00 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025

    ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 second quarter financial results before the market opens on Friday, August 1, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI52cf21ec526142b8b6142d07c87cfcf9. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available re

    7/25/25 4:05:00 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    IRADIMED CORPORATION Announces First Quarter 2025 Financial Results

    Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in 2024.Reports GAAP diluted EPS of $0.37 and non-GAAP diluted EPS of $0.42 for the first quarter of 2025, which are increases of 16% and 17%, respectively, compared to the same period in 2024.Declares a regular quarterly cash dividend of $0.17 per common share for the second quarter of 2025, payable on May 30, 2025. WINTER SPRINGS, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its

    5/5/25 7:00:00 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    $IRMD
    Leadership Updates

    Live Leadership Updates

    View All

    IRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of Directors

    WINTER SPRINGS, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022. Following the appointment of Ms. Scharen-Guivel, the Board will comprise five directors, three of whom are independent. "We are pleased to welcome Hilda Scharen-Guivel to the Iradimed Board," said Roger Susi, President and Chief Executive Officer of the Company. "Hilda's deep experience in regulatory oversight in the medical device industry will be invaluable to Iradimed as we develop new products and grow our business to better serve patients." Ms. Scharen-Guivel,

    10/6/22 4:05:00 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    Perimeter Medical Imaging AI Appoints Experienced MedTech Executive, Chris Scott, as Chief Financial Officer

    Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced the appointment of Chris Scott as Chief Financial Officer, effective immediately. Jeremy Sobotta, Perimeter's Chief Executive Officer stated, "We are pleased to welcome Chris to the Perimeter leadership team. Chris is a collaborative leader who brings a wealth of public company experience directly relevant to Perimeter as we continue to execute on our commercial, clinical, and corporate development goals. Previously

    6/1/22 9:35:00 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    $IRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by iRadimed Corporation

    SC 13G/A - IRADIMED CORP (0001325618) (Subject)

    11/14/24 3:35:27 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

    SC 13G/A - IRADIMED CORP (0001325618) (Subject)

    2/13/24 4:25:25 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

    SC 13G/A - IRADIMED CORP (0001325618) (Subject)

    2/12/24 12:03:30 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care